JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit

NCT06244862 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Hemophagocytic Syndromes

Interventions

DRUG: Ruxolitinib

Sponsor

Assistance Publique - Hôpitaux de Paris